<DOC>
	<DOCNO>NCT02590809</DOCNO>
	<brief_summary>Hypertrophic cardiomyopathy ( HCM ) frequent genetic cardiac disease characterize asymmetric hypertrophic . In two third patient , obstruction blood ejection observe within left ventricle name leave ventricular outflow tract obstruction ( LVOTO ) . This phenomenon occur rest exercise associate symptom dyspnea , dizziness chest pain significantly limit day life adaptation . To , medical interventional treatment betablocacker , calcium blocker septal alcoholisation surgery present limit efficiency . Recent study investigator group reveal new concept role venous return LVOTO . Therefore investigator hypothesis BX1514M generate venous vascular constriction , could improve symptom HCM patient reduce LVOTO .</brief_summary>
	<brief_title>Hypertrophic Cardiomyopathy Symptom Release BX1514M</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<criteria>Patients typical atypical hypertrophic cardiomyopathy ( HCM ) confirm image modality ( echo MRI ) and/or genetic test relative history HCM Left ventricular obstruction exercise treadmill ( 50 mmHg ) Positive response leg lift test ( obstruction reduction 20 mmHg ) rest early recovery phase Daily symptoms shortness breath exercise ( NYHA23 ) , non coronary chest pain , dizziness Correct ultrasound windows quality Sinus rhythm Optimal medical treatment For woman , pregnancy test contraception Written consent form obtain Previous treatment BX1514M Extracardiac pathology life expectancy 1 year No capability consent form write Pregnancy woman Secondary hypertension hypertrophy , secondary valvular disease hypertrophy Permanent atrial fibrillation Severe ventricular arrhythmia without Implantable Cardioverter Defibrillator ( ICD ) Severe coronary disease Severe non stabilize hypertension Severe cardiopathy ( ejection fraction 40 % demonstrate elevated end diastolic pressure pulmonary pressure 60 mmHg ) Bradycardia Narrow angle glaucoma Vascular prethrombotic disease Vascular spam Thyrotoxicosis Pheochromocytoma Severe renal failure ( &lt; 30ml/mn ) Patients risk urinary retention secondary prostatic severe disease Raynaud 's disease Non selective Monoamine Oxidase Inhibitors ( MAOIs ) , iproniazid , nialamide ephedrine , methylphenidate , phenylephrine , pseudoephedrine digitalic Procedures modify peripheral venous return Participation research protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Left ventricular obstruction</keyword>
</DOC>